Istanbul
,
Turkey
12 - 15 May 2026
European Congress on Obesity (ECO 2026)
Presentation schedule and materials
Tuesday, 12 May 2026
14:25
- 15:35
TRT
AD04.02
ORAL PRESENTATION
Time to sustainable weight reduction thresholds with semaglutide 7.2 mg in adults with obesity: A post hoc analysis of the STEP UP trial
Georgia Argyrakopoulou1; Christine S. Fuchs Jacobsen2; Swathi Gopal3; Deborah. Horn4; Maria Quiroga5; John B. Buse6
MATERIALS AVAILABLE
14:35
- 14:45
TRT
AD04.03
ORAL PRESENTATION
CagriSema and Achievement of BMI and Waist-to-Height Ratio Treatment Targets: REDEFINE 1
Luca Busetto1; Cynthia Karenina Osorto Contreras2; Mikkel Hovden Christensen2; Deborah Horn3; Carel W. Le Roux4,5; Barbara Mcgowan6; Claire Prener Miller2; W. Timothy Garvey7
MATERIALS AVAILABLE
14:45
- 14:50
TRT
AD04.04
ORAL PRESENTATION
REDEFINE 1: Effect of CagriSema 2.4 mg/2.4 mg on Body Composition, Muscle Strength and Physical Function
Eric Ravussin1; Cynthia Karenina Osorto Contreras2; Gema Frühbeck3; Christoffer Andersen Hagemann2; Alexander D. Miras4; John Morton5; Niels Zeuthen2; Carla M. Prado6
MATERIALS AVAILABLE
16:15
- 17:45
TRT
Symposium
Semaglutide in clinical practice: oral & injectable pathways for weight loss and health gain
Deborah Bade Horn
;
Sean Wharton
;
John Wilding
;
Katharina Timper
MATERIALS AVAILABLE
Wednesday, 13 May 2026
13:45
- 15:15
TRT
Symposium
Expanding frontiers in cardiometabolic care with amylin-based therapies
Carel le Roux
;
Gema Frühbeck
;
Anna Secher
;
Kirsi Pietiläinen
;
Matthias Blüher
;
Donna Ryan
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO1.085
POSTER
Cagrilintide Does Not Affect the Exposure of the Combined Oral Contraceptive Ethinyloestradiol/Levonorgestrel or Gastric Emptying as Measured by the Paracetamol Absorption Test
Jennifer van der Horst1; Niels-Peter Becker1; Julie B. Hjerpsted2; Katrine Kirkeby1; Michal Tomasz Marzec1; Gaetano Morelli3; Louise Witten1
MATERIALS AVAILABLE
Coming soon
18:00
- 19:15
TRT
PO1.084
POSTER
Once-Weekly Subcutaneous CagriSema Does Not Affect the Exposure of Atorvastatin or Warfarin in People Living With Overweight or Obesity
Valdemar Funch Uhre1; Niels-Peter Becker1; Katrine Kirkeby1; Michal Tomasz Marzec1; Gaetano Morelli2; Louise Witten1
MATERIALS AVAILABLE
Thursday, 14 May 2026
13:00
- 15:00
TRT
PO4.274
POSTER
Early Responders to Oral Semaglutide 25 mg: A Post Hoc Analysis of the OASIS 4 Trial
W. Timothy Garvey1; Oscar Birkhan2; Naveen Rathor2; Chaithra Shaji3; Domenica Rubino4
MATERIALS AVAILABLE
13:00
- 15:00
TRT
LBP4.079
POSTER
Gastrointestinal Tolerability of Once-Daily Oral Semaglutide 25 mg in Adults with Overweight or Obesity, and the Relationship with Weight Loss: A Post Hoc Analysis of the OASIS 4 Trial
Domenica Rubino1; Oscar Birkhan2; Agnieszka Klimek-Abercrombie2; Chaithra Shaji3 ; Minh Chau Tran2; Sean Wharton4
MATERIALS AVAILABLE
13:00
- 14:00
TRT
PO4.261
POSTER
Treatment Effect of CagriSema 2.4 mg/2.4 mg in Adults With Early-Onset Overweight or Obesity in REDEFINE 1
Matthias Blüher1; Cynthia Karenina Osorto Contreras2; Jason C. G. Halford3; Aaron S. Kelly4; Ananda Kosuvaripalli5; Eva Winning Lehmann2; Kirsi H. Pietiläinen6; Dror Dicker7
MATERIALS AVAILABLE
13:00
- 15:00
TRT
PO4.252
POSTER
Assessing Cardiovascular Safety and Outcomes With the Combination of Cagrilintide and Semaglutide (CagriSema): REDEFINE 3 Randomised Clinical Trial Baseline Characteristics and Methods
Matthew A. Cavender1; Ania M. Jastreboff2; Alice Y. Y. Cheng3; Melanie J. Davies4,5; Lucienne Donaldson6; Lars-Ole Gerlach6; Silas Hinsch Gylvin6; Jacob Bonde Jacobsen6; Nikolaus Marx7; Cynthia Karenina Osorto Contreras6; Carel W. Le Roux8, A. Michael Lincoff9
MATERIALS AVAILABLE
13:00
- 15:00
TRT
PO4.268
POSTER
OASIS 4: Efficacy of Oral Semaglutide 25 mg in Obesity Treatment Targets and Low-risk Outcomes for Cardiometabolic Risk Factors
Carel W. Le Roux1; Oscar Birkhan2; Naveen Rathor2; Domenica Rubino3; Chaithra Shaji4; Luca Busetto5
MATERIALS AVAILABLE
13:00
- 15:00
TRT
LBP4.160
POSTER
Improved Quality of Life With CagriSema in People with Overweight or Obesity and Poor Physical Function at Baseline: A Post Hoc Analysis of the REDEFINE 1 Trial
Domenica Rubino1; Jaime P. Almandoz2; Christine Poitou3,4; Tobias Freyberg Justesen5; Ronette L. Kolotkin6-9; Cindy Pau10; Lisa von Huth Smith5; Zara Rebecca Stisen5; Niels Zeuthen5; Kirsi H. Pietiläinen11,12
MATERIALS AVAILABLE
13:45
- 15:15
TRT
Symposium
Let’s talk about heart and liver health in obesity management
Donna Ryan
;
Matt Cavender
;
Aleksander Krag
;
Josep Vidal
MATERIALS AVAILABLE
18:00
- 19:15
TRT
POSTER
REDEFINE 1 Qualitative Interview Sub-study Exploring Patient Experiences With Weight and Physical Functioning
Claire Ervin, Sheri Fehnel, Tobias Freyberg Justesen, Joe Nadglowski, Lindsey Norcross, Olivia Svolgaard, Lisa von Huth Smith, Ronette Kolotkin
MATERIALS AVAILABLE
18:00
- 18:15
TRT
AD17.06
ORAL PRESENTATION
CagriSema Reduces Predicted Atherosclerotic Cardiovascular Disease Risk in Adults With Overweight or Obesity: The REDEFINE 1 Trial
Subodh Verma1; Morten Böttcher2; Paul Brown3; Dror Dicker4; Domenica Rubino5; Paolo Sbraccia6; Arya M. Sharma7; Lærke Smedegaard3; Rasmus Sørrig3; W. Timothy Garvey8
MATERIALS AVAILABLE
18:00
- 18:15
TRT
PO4.256
POSTER
Characterisation of CagriSema dose reductions in the REDEFINE 1 trial
W. Timothy Garvey1; Jaime P. Almandoz2; Mikkel Hovden Christensen3; Cynthia Karenina Osorto Contreras3; Anthony N. Fabricatore4; Thomas Bo Jensen3; Michael G. Knight5; Kirsi H. Pietiläinen6;7; Carel W. le Roux8;
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.219
POSTER
Zenagamtide, a Novel, Long-Acting, Unimolecular GLP-1 and Amylin Receptor Agonist, Does Not Delay Gastric Emptying
Maria B. N. Gabe1;Ruben Duque do Vale1; Swathi Gopal1; Tobias Karlsson1;Gaetano Morelli2; Anne Flint1
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.218
POSTER
Zenagamtide, a Novel, Long-Acting, Unimolecular GLP-1 and Amylin Receptor Agonist, Does Not Impact the Pharmacokinetics of the Combined Oral Contraceptive, Levonorgestrel/Ethinylestradiol
Maria B. N. Gabe1;Ruben Duque do Vale1; Swathi Gopal1; Tobias Karlsson1;Gaetano Morelli2; Anne Flint1
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.267
POSTER
Renal or Hepatic Impairment Does Not Affect the Pharmacokinetics, Safety or Tolerability of Subcutaneous Cagrilintide
Mette J. F. Nielsen1; Niels-Peter Becker1; Helene H. Hansen Duus1; Katrine Kirkeby1; Viera Kupčová2; Britt W. Lauenborg1; Benjamin Low1; Olivia Svolgaard1; Louise Witten1
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.478
POSTER
OUTSTEP programme: A multi-dimensional patient-centred approach to understanding patient experiences, real-world utilisation and the effectiveness of semaglutide in obesity management
Arya M Sharma1; Jennifer L. Baker2; Leyla Hernandez Donoso3; Priyanka Padwal4; Ricardo Reynoso3; Hanen Samouda5,6; Michael Vallis7; Bruno Halpern8,9
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.310
POSTER
Predicting the effectiveness of semaglutide 2.4 mg on weight change in a real-world population: An AI simulation model proof-of-concept framework in France
Sébastien Czernichow1; Emmanuel Disse2; Jennifer L. Baker3; Leyla Hernandez Donoso4; Estelle Frappe5; Linong Ji6; Ricardo Reynoso4; Paolo Sbraccia7; Hironori Waki8; Arya M Sharma9
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.198
POSTER
Effectiveness and use of digital tools to support obesity management medications: An AI systematic literature review (the OUTSTEP 4 study)
Germano Ferreira1; Andreea Ciudin2-5; Leyla Hernandez Donoso6; Idit Dotan7,8; Linong Ji9; Priyanka Padwal10; Ricardo Reynoso6; Michael Vallis11; Arya M Sharma12
MATERIALS AVAILABLE
18:00
- 19:15
TRT
PO4.307
POSTER
Encore, SELECT-LIFE: A non-interventional follow-up study investigating the long-term effects of semaglutide in participants from the SELECT trial
Ildiko Lingvay1; John E. Deanfield2; María De Los Angeles Quiroga Peláez3; Steven E. Kahn4; A. Michael Lincoff5; Jorge Plutzky6; Stine D. Ross3; Peter E. Weeke3; Donna H. Ryan7; [encore]
MATERIALS AVAILABLE
18:05
- 18:10
TRT
PO4.002
POSTER
Early Responders to Semaglutide 7.2 mg: A Post Hoc Analysis of the STEP UP Trial in Adults with Obesity
Dror Dicker1; Deborah B. Horn 2; Christine S. Fuchs Jacobsen 3; Swathi Gopal 4;*Maria Quiroga 5; Sean Wharton 6
MATERIALS AVAILABLE
18:35
- 18:40
TRT
PO4.008
POSTER
CagriSema 2.4 mg/2.4 mg Improves Metabolic Syndrome in Adults With Overweight or Obesity, Without Type 2 Diabetes: A Post hoc Analysis of REDEFINE 1
Matthias Blüher1; Kasper Adelborg2; Melanie J. Davies3; Ildiko Lingvay4; Christian Bøge Lyndgaard2; Rasmus Sørrig2; John P. H. Wilding5; Ania M. Jastreboff6
MATERIALS AVAILABLE
Friday, 15 May 2026
09:50
- 10:00
TRT
AD19.03
ORAL PRESENTATION
Efficacy and Safety of Semaglutide in Individuals Aged ≥65 Years: A Pooled Analysis of the STEP Trials
Luca Busetto1; Niklas Kahr Rasmussen2; Naveen Rathor2; Domenica Rubino3; Lauren Wilson4; Dror Dicker5,6
MATERIALS AVAILABLE
10:10
- 10:20
TRT
AD19.05
ORAL PRESENTATION
Relationship Between Mean CagriSema Dose and Weight Loss in the REDEFINE 1 Trial
W. Timothy Garvey1; Jaime P. Almandoz2;Mikkel Hovden Christensen3; Cynthia Karenina Osorto Contreras3; Anthony N. Fabricatore4; Thomas Bo Jensen3; Michael G. Knight5; Kirsi H. Pietiläinen6,7; Carel W. le Roux8
MATERIALS AVAILABLE
10:20
- 10:30
TRT
AD19.06
POSTER
Characteristics, Attitudes and Experiences of Individuals Using Injectable Semaglutide for Obesity Management: An Interim Analysis of the OUTSTEP 1 Study
Michael Vallis1; Salah Abusnana2; Jennifer L. Baker3; Andreea Ciudin4-7; Leyla Hernandez Donoso8; Sandra Elia9; Dmitry Estulin8; Bruno Halpern10; 11; Samantha Hocking12; Hyuk-Sang Kwon13; Susanne Reger-Tan14; Ricardo Reynoso8; Hanen Samouda15; 16; Arya M. Sharma17
MATERIALS AVAILABLE
Keywords